Yayun Liang
Overview
Explore the profile of Yayun Liang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liang Y, Nephew K, Hyder S
J Cancer Sci Clin Ther
. 2023 Dec;
7(1):1-8.
PMID: 38105923
Introduction: Epithelial Ovarian Cancer (EOC) cells express enzymes in the cholesterol biosynthetic pathway, making this pathway an attractive therapeutic target for controlling ovarian cancer. Potent small molecule inhibitors of one...
2.
Liang Y, Besch-Williford C, Hyder S
Breast Cancer Res Treat
. 2022 Jan;
192(1):53-63.
PMID: 35037188
Purpose: Most hormone-dependent human breast cancers develop resistance to anti-hormone therapy over time. Our goal was to identify novel treatment strategies to avoid this drug resistance and thereby control hormone-dependent...
3.
Liang Y, Besch-Williford C, Cook M, Belenchia A, Brekken R, Hyder S
Breast Cancer (Dove Med Press)
. 2019 Sep;
11:249-259.
PMID: 31534364
Background: Approximately 15-20% of all human breast cancers are classified as triple-negative because they lack estrogen and progesterone receptors and Her-2-neu, which are commonly targeted by chemotherapeutic drugs. New treatment...
4.
Liang Y, Mafuvadze B, Besch-Williford C, Hyder S
Breast Cancer (Dove Med Press)
. 2018 Apr;
10:53-67.
PMID: 29606888
Background: Between 30 and 40% of human breast cancers express a defective tumor suppressor p53 gene. Wild-type p53 tumor suppressor protein promotes cell-cycle arrest and apoptosis and inhibits vascular endothelial...
5.
Liang Y, Goyette S, Hyder S
Breast Cancer (Dove Med Press)
. 2017 Jul;
9:487-494.
PMID: 28744156
Clinical trials and studies have shown that postmenopausal women undergoing combination hormone replacement therapy containing estrogen and progestin have an increased risk of breast cancer compared with women taking estrogen...
6.
Goyette S, Liang Y, Mafuvadze B, Cook M, Munir M, Hyder S
Breast Cancer (Dove Med Press)
. 2017 Jun;
9:347-357.
PMID: 28579829
Clinical trials and studies have shown that combination estrogen/progestin hormone replacement therapy, but not estrogen therapy alone or placebo, increases breast cancer risk in postmenopausal women. Using animal models, we...
7.
Cook M, Liang Y, Besch-Williford C, Hyder S
Breast Cancer (Dove Med Press)
. 2017 Jan;
9:9-19.
PMID: 28096694
Most breast cancer-related deaths from triple-negative breast cancer (TNBC) occur following metastasis of cancer cells and development of tumors at secondary sites. Because TNBCs lack the three receptors targeted by...
8.
Liang Y, Mafuvadze B, Aebi J, Hyder S
Onco Targets Ther
. 2016 Jun;
9:3223-32.
PMID: 27313468
Standard treatment for primary prostate cancer includes systemic exposure to chemotherapeutic drugs that target androgen receptor or antihormone therapy (chemical castration); however, drug-resistant cancer cells generally emerge during treatment, limiting...
9.
Cook M, Liang Y, Besch-Williford C, Goyette S, Mafuvadze B, Hyder S
Springerplus
. 2015 Aug;
4:444.
PMID: 26312209
Purpose: Clinical trials and epidemiological evidence have shown that combined estrogen/progestin hormone replacement therapy, but not estrogen therapy alone, increases breast cancer risk in post-menopausal women. Previously we have shown...
10.
Mafuvadze B, Liang Y, Hyder S
Oncol Rep
. 2014 Jul;
32(4):1727-33.
PMID: 25051231
Breast cancer cells express enzymes that convert cholesterol, the synthetic precursor of steroid hormones, into estrogens and androgens, which then drive breast cancer cell proliferation. In the present study, we...